XML 29 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment, Customer And Geographic Information
 3 Months Ended
Mar. 31, 2012
Segment, Customer And Geographic Information [Abstract]  
Segment, Customer And Geographic Information

Note 13. Segment, Customer and Geographic Information

The Company continues to operate in only one segment, blood safety. The Company's chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services are minimal.

The Company's operations outside of the United States include a wholly-owned subsidiary headquartered in Europe. The Company's operations in the United States are responsible for the research and development and global commercialization of the INTERCEPT Blood System, as discussed in further detail below, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, The Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.

The Company had the following significant customers that accounted for more than 10% of the Company's total product revenue, all of which operate in a country outside of the United States, during the three months ended March 31, 2012 and 2011 (in percentages):

 

     Three Months Ended
     March 31,
     2012   2011

Etablissement Francais du Sang

    30%   23%

Movaco, S.A.

    18%   27%

Delrus Inc.

    17%   *

Service Francophone du Sang

    *   10%

 

* Represents an amount less than 10% of product revenue.

The Company also recognized government grants and cooperative agreements revenue of $0.1 million, which represented 1% of total revenue, during the three months ended March 31, 2012 and $0.4 million, which represented 7% of total revenue, during the three months ended March 31 2011. The Company has received awards under cooperative agreements with the Army Medical Research Acquisition Activity division of the Department of Defense since February 2001. The Company received these awards in order to develop its pathogen inactivation technologies for the improved safety and availability of blood that may be used by the United States Armed Forces for medical transfusions. Under the terms of the cooperative agreements, the Company is conducting research on the inactivation of infectious pathogens in blood, including unusual viruses, bacteria and parasites that are of concern to the United States Armed Forces. This funding supports advanced development of the Company's red blood cell system.